医学资讯: PD-1抗体正式成为肺癌首选治疗！

数据对比如下图：

文章部分摘自网络，著作权归原作者所有

参考文献

1.Martin Reck,, et al., Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 2016.

2.http://www.forbes.com/sites/matthewherper/2016/10/09/bristols-cancer-drug-results-are-worse-than-expected-while-mercks-are-better/#401bc1295d9a

3.http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-metastatic-nsclc-